Hematology

ASH 2024

Questions discussed in this category

With the data from AALL1731, how is blinatumomab being implemented for SR and HR leukemia patients not previously planned/randomized to receive blinatumomab?

Based on AALL1731, if in maintenance, is there a certain point at which it is incorporated, or a certain maintenance cycle which it is no longer offer...

1 Answer available

What hydroxyurea dose do you target for HbSC disease?

1 Answer available

Is there a role for DOAC use for patients with unprovoked PE, that have had recent sleeve gastrectomy with duodenal bypass?

Or do you generally prefer warfarin/non-DOAC agents? Do you consider trialing DOACs and testing anti-Xa DOAC levels to assess for absorption?

1 Answer available

Would you consider daratumumab monotherapy as standard of care for smoldering multiple myeloma based on the AQUILA trial?

AQUILA trial - NEJM

3 Answers available

Papers discussed in this category

J Thromb Haemost, 2021 Jul 14

Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: Updated communication from the ISTH SSC Subcommittee on Control of Anticoagulation.

Blood advances, 2023 Jan 24

Direct oral Xa inhibitors for the treatment of venous thromboembolism after bariatric surgery.

Thrombosis and haemostasis, 2018 Feb 12

International Council for Standardization in Haematology (ICSH) Recommendations for Laboratory Measurement of Direct Oral Anticoagulants.

The New England journal of medicine, 2024 Dec 09

Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma.

Blood cancer journal, 2020 Oct 16

International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM).

Blood advances, 2023 Nov 14

CD38 antibody re-treatment in daratumumab-refractory multiple myeloma after time on other therapies.

British journal of haematology, 1997-09

Cellular effects of hydroxyurea in Hb SC disease.

Journal of pediatric hematology/oncology, 2001

Hydroxyurea therapy for pediatric patients with hemoglobin SC disease.

Pediatric blood & cancer, 2013-02

Hydroxyurea treatment of children with hemoglobin SC disease.

NEJM evidence, 2024 Dec 08

Hydroxyurea for Children and Adults with Hemoglobin SC Disease.

Hematology

ASH 2024

Questions discussed in this category

Papers discussed in this category

Related Topics in Hematology